We observed that palbociclib paradoxically stabilizes p21/p27‐free cyclin D‐CDK4/6 complexes that become hyperactive upon palbociclib withdrawal, potentially inducing a burst of tumour cell cycle progression that might open a window of increased responsiveness to genotoxic therapies [64]. The gene discussed is CDKN1B; the disease is neoplasm.